Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.
Lucia Masarova, MD
Advertisement
Articles by Lucia Masarova, MD
Lucia Masarova, MD, discusses the single-arm multicenter phase 2 EXCEED-ET trial of ropeginterferon alfa-2b-njft in adult patients with essential thrombocythemia.
Lucia Masarova, MD, discusses future research efforts in myeloproliferative neoplasms.
Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.
Advertisement
Latest Updated Articles
Dr. Masarova on Future Research in MPNsPublished: October 19th 2020 | Updated:
Dr. Masarova on the Safety of JAK Inhibitor/Targeted Therapy Combos in MyelofibrosisPublished: October 5th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5